Using the abYsis database for drug discovery
Posted 30th April 2021 by Nicholas Noakes
Professor Andrew Martin, UCL, speaking at the 4th Global Pharma R&D AI, Data Science and Informatics Summit, described using the abYsis database and workbench for drug discovery. He showed how it is possible to explore an annotate antibody sequence and structure, including comparisons with observed residue distributions. The database can also aid with humanization by making sequences more human and library design.
Harvesting the power of the cell’s own protein degradation mechanisms in drug discovery
Posted 21st October 2020 by Joshua Sewell
Constant production of proteins in living cells is subject to strict quality and concentration control. The ubiquitin-protease system (UPS) is one of the systems responsible for degrading misfolded and damaged proteins. Also, short-lived regulatory proteins that control many critical cellular processes, including cell cycle progression, cell proliferation and differentiation, cell signalling and transcription are degraded by UPS.1
How deep learning is transforming medical imaging: image search
Posted 29th July 2020 by Liv Sewell
Five or six years ago, I was looking for a strategic direction for the KIMIA Lab. We started with the problems. We asked, ‘What problems do we have in medical imaging?’
PROTAC drug discovery – prior preparation and planning
Posted 1st July 2020 by Liv Sewell
“By failing to prepare, you are preparing to fail” so said Benjamin Franklin, and as a veteran of early stage drug discovery you can bet that I, like you, have seen my fair share of successes but also more failures than I’d like.
Slides from the 4th Medicinal Chemistry & Protein Degradation Summit
Posted 26th November 2019 by Joshua Sewell
The 4th Medicinal Chemistry & Protein Degradation Summit provided two days of fascinating topics and case studies about AI-assisted lead optimisation, DNA encoded libraries and the use of data and informatics in drug-discovery. We have made the following presentation slides available from Greg Makara, Paul Colbon and Yugal Sharma.
Reshaping drug discovery with deep learning and polypharmacology
Posted 23rd October 2019 by Joshua Sewell
Cyclica is a Toronto-based biotech that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. We spoke to their Chief Scientific Officer Andreas Windemuth.
Will the intersection of blockchain and AI inspire the Pharma R&D Renaissance?
Posted 30th September 2019 by Joshua Sewell
Global Engage spoke to Scott Kahn ahead of the 3rdGlobal Pharma R&D Informatics and AI Congress. Scott is the CIO of Luna PBC, the entity that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
This is the second half of that conversation, where Scott discusses the challenges of distributive ledger technologies such as Blockchain, and their intersection with AI for Pharma R&D.
How to revolutionise clinical trials: engaging with participants as partners
Posted 23rd September 2019 by Joshua Sewell
Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.